Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
NCT00880399
Study timeline
Study start (unknown)2009-03-01Date precision: day
Registry last updated2017-09-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Depressive Disorder, Majorunresolved
Interventions
orvepitantDRUG
placeboOTHER
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
New YorkNew York, United States1TorontoOntario, Canada1SeattleWashington, United States1BirminghamAlabama, United States1OrlandoFlorida, United States1The BronxNew York, United States1OttawaOntario, Canada1ScottsdaleArizona, United States1ToledoOhio, United States1Beverly HillsCalifornia, United States1Overland ParkKansas, United States1BradentonFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00880399 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.